We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

13 hedge funds and large institutions have $484K invested in Monopar Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

28% more capital inflows, than outflows

Capital inflows: $37.7K | Capital outflows: $29.5K

8% more funds holding

Funds holding: 12 → 13 (+1)

0.03% more ownership

Funds ownership: 1.62% → 1.65% (+0.03%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
13
Holders Change
+1
Holders Change %
+8.33%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$37.2K
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$385
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$23
4
Wells Fargo
Wells Fargo
California
+$11

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$25.8K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$2.69K
3
FinTrust Capital Advisors
FinTrust Capital Advisors
South Carolina
-$1K
4
Morgan Stanley
Morgan Stanley
New York
-$11

MNPR Hedge Fund Activity: Q2 2022 in Review

13 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2022, worth a combined $484K — down 9.2% from $533K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MNPR positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was UBS Group, adding an estimated $37.2K. The largest seller was BlackRock, cutting an estimated $25.8K.

  • 13 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2022, up from 12 in Q1 2022.
  • Funds reported $484K of Monopar Therapeutics stock for Q2 2022, down 9.2% quarter-over-quarter.
  • 2 funds opened new Monopar Therapeutics positions in Q2 2022 and 1 closed out, a net change of +1 holder.
  • The largest Monopar Therapeutics buyer in Q2 2022 was UBS Group, an estimated $37.2K added.
  • The largest Monopar Therapeutics seller in Q2 2022 was BlackRock, an estimated $25.8K sold.

Based on aggregated 13F filings for Q2 2022.